ATPBD4 Activators
ATPBD4 activators encompass a diverse group of chemical compounds that, while not directly interacting with the ATPBD4 protein, promote an intracellular environment that can enhance the protein's activity. This class of activators functions primarily through the modulation of second messenger systems, particularly the cyclic nucleotides cAMP and cGMP. The primary mechanism by which these compounds exert their effect is through the inhibition of phosphodiesterases (PDEs), which are enzymes responsible for the breakdown of cAMP and cGMP. By inhibiting PDEs, activators such as caffeine, theophylline, rolipram, and sildenafil lead to increased levels of these cyclic nucleotides within the cell. Elevated cAMP and cGMP concentrations can have various downstream effects, including enhanced ATP synthesis and availability, which is critical for the function of ATPBD4. This increase in ATP availability is crucial, as ATPBD4 is presumed to require ATP for its function.
Additionally, certain activators within this class operate by directly stimulating enzymes that produce cyclic nucleotides. Compounds like forskolin and isoproterenol target adenylate cyclase, leading to increased cAMP production. Others like YC-1 act onsoluble guanylate cyclase to elevate cGMP independent of nitric oxide pathways. By augmenting the levels of cyclic nucleotides, these activators indirectly improve the bioenergetic status of cells, favoring processes that rely on adequate ATP levels. Consequently, this creates a favorable environment for ATPBD4, which is dependent on ATP for its activity. These compounds, therefore, act as indirect facilitators of ATPBD4 function by ensuring the cellular energy supply meets the demands of various biological processes, including those yet to be fully elucidated functions of ATPBD4, encoded by the gene DPH6. The wide-ranging effects of increased cyclic nucleotide levels also include vasodilation, improved oxygen delivery, and nutrient uptake, all of which can indirectly contribute to the optimal functioning of ATPBD4.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine, a phosphodiesterase inhibitor, can increase intracellular cAMP levels. Elevated cAMP may enhance the activity of ATPBD4 by promoting a cellular environment that favors ATP synthesis and availability, indirectly supporting ATPBD4’s function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly activates adenylate cyclase, leading to an increase in cAMP levels. This upregulation can enhance ATP availability, indirectly stimulating ATPBD4 activity which relies on adequate ATP levels for its function. | ||||||
Sodium nitroprusside dihydrate | 13755-38-9 | sc-203395 sc-203395A sc-203395B | 1 g 5 g 100 g | $43.00 $85.00 $158.00 | 7 | |
Sodium Nitroprusside releases nitric oxide, which activates guanylate cyclase, increasing cGMP levels. Elevated cGMP can indirectly enhance ATPBD4 activity through vasodilation and improved cellular energy status. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline is a phosphodiesterase inhibitor that can raise intracellular cAMP concentrations, possibly leading to indirect stimulation of ATPBD4 by promoting conditions that favor ATP synthesis. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, leading to elevated cAMP levels. Increased cAMP may indirectly support ATPBD4 activity by fostering an environment with enhanced ATP generation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can raise cAMP levels, indirectly aiding ATPBD4 function by boosting ATP synthesis and bioavailability within cells. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterase, increasing levels of both cAMP and cGMP, which may indirectly enhance ATPBD4 activity by improving cellular energy states. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Papaverine inhibits phosphodiesterases, leading to increased cAMP and cGMP levels. This elevation may indirectly augment ATPBD4 activity by creating a cellular environment conducive to ATP synthesis. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
YC-1 stimulates soluble guanylate cyclase independent of nitric oxide, raising cGMP levels, which could indirectly support ATPBD4 function by enhancing the cellular energy status. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterase 5, which increases cGMP levels and may indirectly support ATPBD4 activity due to improved cellular energy balance and function. | ||||||